Project Grant R01HL181536
Award Date 8/10/26
Completion Date 4/30/30
Dollars Obligated $837K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Roxbury, MA 02118, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the Trustees of Boston University $245,250 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study the phenotypes and genesis of arginase 1-positive myeloid cells in pulmonary tuberculosis using a genetic mouse model of chronic TB. The research uses the B6.SST1S mouse model, which develops human-like organized necrotic granulomas after aerosol, intravenous, or subcutaneous infection...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $768,600 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the lung macrophage efflux system in the pathogenesis of Mycobacterium tuberculosis. The research aims to identify host-directed therapeutic targets for tuberculosis treatment. The work focuses on two objectives: defining the role of the multidrug resistance transporter MDR1 in M. tuberculosis survival...
- The National Heart, Lung, and Blood Institute awarded Boston University a Project Grant of $1,605,354 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung interstitial macrophages and their role in bacterial pneumonia defense. The research examines two major subsets of lung interstitial macrophages—CD206+ and CD206—that occupy distinct anatomic niches and perform different immune functions. Preliminary findings indicate that both subsets...
- The National Heart, Lung, and Blood Institute awarded The Washington University $680,379 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of sphingolipid biosynthesis during lung infection, specifically examining how SPTLC2, an essential enzyme subunit in sphingolipid synthesis, affects survival during Mycobacterium tuberculosis infection in CD11C+ lung macrophages and dendritic cells. The project addresses immune response mechanisms...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded Emory University $123,654 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct mentoring in patient-oriented translational research on tuberculosis, HIV, and lung health (Project Grant K24HL189236). The award funds research to identify risk factors for post-TB lung disease (PTLD) and develop evidence-based interventions to prevent PTLD and improve long-term respiratory health among TB...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Boston University $712,630 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate functional heterogeneity of alveoli and early responses to airborne agents. The recipient will develop and apply the Crystal Ribcage, a novel intravital imaging platform, to visualize real-time, high-resolution dynamics of the intact, ventilating lung. The research will define the anatomy, physiology,...
- The National Heart Lung and Blood Institute awarded the President and Fellows of Harvard College (operating as Harvard Medical School) $3,793,888 under federal grant R01HL178712 on September 20, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research to identify host- and pathogen-specific risk factors for post-tuberculosis lung disease (PTLD) among successfully treated TB patients in Lima, Peru. The research team will evaluate 1,000 successfully...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $798,107 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish a tissue-based understanding of tuberculosis-associated lung fibrosis and post-TB lung disease pathology. The project creates a baseline understanding of molecules and cells driving fibrogenesis during TB infection, with the goal of identifying adjunctive therapies to modulate tissue...
- The National Heart, Lung, and Blood Institute awarded Oregon Health & Science University $218,728 in project grant funding on March 18, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This award funds spatial immunophenotyping of tuberculosis granulomas, with work performed at OHSU's Portland, Oregon campus through September 16, 2029. The project applies an extensive panel of Mycobacterium tuberculosis antigen-specific probes—including commercial antibodies, novel...
- The National Heart, Lung, and Blood Institute awarded Trustees of Boston University $1.618 million on July 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of PACC1, a proton-gated chloride channel, in host defense against bacterial infections and sepsis. The research characterizes PACC1 function in phagocytic clearance of bacteria by tissue-resident macrophages during sepsis. Preliminary studies show that PACC1 knockout mice exhibit high...